Business ❯ Pharmaceuticals ❯ Drug Development

Clinical Research

Regulatory Affairs Japanese Pharmaceutical Companies Eli Lilly Phase 3 Trials FDA Approvals Neurocrine Biosciences AstraZeneca Funding Sources Innovation in Healthcare Radiopharmaceuticals Boehringer Ingelheim Wave Life Sciences Pharmaceutical Industry Trends Market Impact Ivonescimab Biologics License Application Monoclonal Antibodies

One Infusion Cuts LDL by Up to 62% in Early Gene‑Editing Trial

Interim NEJM data show dose‑dependent PCSK9 knockdown with an initially favorable safety signal prompting Fast Track status.

FDA Launches First Real-Time Clinical Trial Pilot With AstraZeneca and Amgen

Allogene Soars on Early ALPHA3 Readout Showing Strong MRD Edge and Clean Safety

IDEAYA Combo Doubles Progression-Free Survival in Uveal Melanoma Trial

Summit Therapeutics Shares Rally as Ivonescimab Trials Near Q2 Readout

Edgewise Reports Favorable Interim Safety in Phase 2 HCM Trial of EDG-7500

Neurocrine’s Valbenazine Misses Phase 3 Goals in Dyskinetic Cerebral Palsy

Datroway Extends Survival Over Chemotherapy in First-Line TNBC Ineligible for Immunotherapy

Study Finds Most With New Focal Epilepsy Need a Year to Gain Seizure Control